News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Investors look to Healthcare for ESG exposure, and Volpara is the poster child
Health & Biotech
ASX Health Stocks: Apiam and Trajan on acquisition trail, Immutep provides updates on Phase 2 trials
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
ScoPo’s Powerplays: AGM season ‘flushes out negative surprises’ but creates buying opportunities
News
10 at 10: These ASX stocks are paying off their investors’ excitement this morning
Health & Biotech
China is about to grant patents like never before, and these ASX stocks have already got some
Health & Biotech
ASX Health Stocks: Intelicare jumps 35pc on AI in-home sensor tech contract for seniors
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Experts
MoneyTalks: Here’s why this fund backs these 2 big ASX biotechs alongside Merck and Novavax
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ScoPo’s Powerplays: Profit-taking on the cards for health stocks that have had good runs
Health & Biotech
ScoPo’s Powerplays: Recent price swings uncovered hidden gems and buying opportunities in healthcare
Health & Biotech
ASX Health Stocks: Memphasys jumps on legal settlement after flaw with its Felix sperm-separating device
Health & Biotech
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
News
